GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

GlaxoSmithKline plc

and Theravance, Inc.

today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.